Sugentech수젠텍

Sugentech remains loss-making on trailing results, with revenue shrinking and the share price down sharply over the past year.

Sugentech, a Korean diagnostics company listed on KOSDAQ, reported trailing twelve-month revenue of ₩9.8B to H1 2026 against an operating loss of ₩18.9B, so its operating margin is about -193%. Revenue fell 6.7% in 2025 after a 41.6% rise in 2024, and the stock closed at ₩4,080 on 2026-10-27, down 40.6% over one year. The data does not include any analyst ratings or forecasts.

What stands out

• Trailing net loss of ₩23.0B and free cash flow of -₩15.7B show the business is still consuming cash.
• Cash of ₩10.0B sits against borrowings of ₩11.5B, and liabilities are 27.3% of equity.
• The stock trades at about 1.0x book value and 7x sales, with no P/E because earnings are negative and no dividend.
• The model's base-case fair value is ₩701 per share, well below the current price; the bear and bull figures listed are ₩985 and ₩301, which look inconsistent with the labels and should be checked against the source.
• Foreign ownership rose slightly to 3.2% over 60 days, while retail investors were net sellers over the last 20 days.

What to watch

• The next quarterly or annual filings, to see whether losses narrow and revenue recovers from the 2025 decline.
• Insider shareholding reports and stock purchase option grants already filed in 2026, which could signal ownership changes.
• Debt versus cash: the data shows borrowings above cash, and the filings do not describe how these will be repaid.